I built a tracker for every hair loss treatment in clinical development Research/Science 1/7/2026
A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community DLQ01: A Better "Minoxidil" PGF2a synthetic analogue.
DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community How far are we from a treatment better than finasteride?
Dutasteride is more effective than finasteride for hair loss as it blocks more of the enzyme causing hair loss. New treatments like stem cell therapies and alternatives to minoxidil are being explored, but major advancements are still years away.
community There’s actually a quite good chance that next year, we might see a new treatment get FDA approval for the first time in nearly three decades.
Breezula, a potential new hair loss treatment, may receive FDA approval soon, but it is expected to be a weaker alternative to finasteride and minoxidil. Concerns include its twice-daily application and possible side effects like HPA axis suppression.
Related Research
6 / 6 resultsresearch What’s new in the treatment of hair loss?
In this article, the authors review the most effective current treatments for hair loss, such as Janus Kinase Inhibitors, Platelet Rich Plasma, anti-androgens, and minoxidil, highlighting the expanding therapeutic options for alopecia.
research Hair Aging Revisited: An Expert Delphi Consensus on Pathogenesis, Clinical Features, and Future Therapies
This Delphi consensus study provides expert insights into hair aging, aims to enhance diagnostic precision and management of age-related hair changes, and identifies possible new therapeutic targets.
research Novel investigational drugs for alopecia areata and future perspectives
In this study, JAK inhibitors were reported as safe and effective treatments for moderate-to-severe chronic alopecia areata, although the appropriate duration of treatment remains uncertain, as stopping these medications often results in relapse.
research Health‐related quality of life of adult and adolescent patients living with alopecia areata in Australia
This study found that alopecia areata significantly impacts both emotional and psychosocial well-being, leading to impaired productivity in adults and adolescents, especially those experiencing more extensive hair loss.
research Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024
This study involved 69 hair experts using a Delphi process to achieve consensus on treating frontal fibrosing alopecia, finding strong agreement on disease monitoring but less on physical and systemic therapies, indicating the need for more research.
research Psychosocial and Occupational Burden on Caregivers of Adolescents With Alopecia Areata in Australia
This study found a significant psychosocial and occupational burden on caregivers of adolescents with alopecia areata in Australia, impacting their mental and emotional well-being and emphasizing the need to recognize the broader effects of the condition beyond the patients themselves.